WillItSurvive
Medical technology and health companies · United States

Omada Health

omadahealth.com ↗

Omada Health runs digital coaching programs employers pay for to manage diabetes, hypertension, and weight.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from September 10, 2026 · Every call on the record Checkpoint: First Investor Day, where renewal and NRR disclosures could confirm or undercut the efficacy story
The call

Omada is growing fast and turning profitable, but an independent study questioning its clinical edge and cheaper AI-only coaching apps sit right underneath its next contract renewals.

Omada Health helps large employers and insurance companies manage diseases like diabetes and heart disease by providing coaching (partly human, partly AI) to sick employees. The company has built a real business with 2,000+ employer customers and relationships with all three major pharmacy benefit managers, plus a new tie-up with Eli Lilly. But copying this business is not actually hard: Teladoc Health already tried it (buying Livongo for $18.5 billion, then writing off $6.6 billion when it didn't work out), and newer competitors like Lark Health are now offering similar coaching using only AI, which costs less. The biggest threat to Omada's survival is whether its results are actually better than doing nothing. A study by an independent research group in 2024 found that Omada's improvement over control was only marginal, which Omada disputes but which could cause customers to cancel. Watch the next two to four quarters of earnings reports (especially the September investor meeting) to see if customers keep renewing their contracts at high rates despite these questions about whether the service actually works.

Why
01
AI pressure: Lark Health. Lark sells AI-only coaching as a cheaper substitute for Omada's human coaches, pressuring the price employers will pay for the human layer. Could AI do the core job? Only partly.
02
Bigger players: Teladoc Health. Teladoc already bought Livongo for $18.5B, wrote down $6.6B, but still owns chronic-care infrastructure it could redeploy against Omada. Could a giant copy it? Yes, easily.
03
What protects it. Contracts with 2,000+ employers and all three major PBMs, plus the Eli Lilly Employer Connect role tying it to GLP-1 access.
What would change this call
Omada's NRR or renewal rate disclosed at Q2 2026 earnings or Sept 10 Investor Day. High renewals despite PHTI critique would show clinical doubts aren't costing contracts.
A top-5 employer or major PBM drops or shrinks Omada's program within a year. Would confirm efficacy doubts are translating into real customer loss.
Teladoc or a major PBM announces an in-house AI-only chronic-care coaching product. Would show incumbents copying Lark's cheaper model and directly contesting Omada's space.
Key numbers
  • FY2025 revenue $260.21M, up 53% YoY (2026-03-05)
  • Q1 2026 revenue $78.05M, members over 1 million (2026-05-11)
  • Market cap ~$1.33B to $1.37B, shares ~$22 (2026-07-22)
Named risks
  • Independent PHTI study found only marginal clinical outcomes versus control, undermining renewal pitch. Severity: high
  • AI-only coaching rivals like Lark Health could compress Omada's human-coach cost premium and margins. Severity: medium
  • GLP-1 drug success could shrink demand for behavior-change programs that are Omada's core TAM. Severity: medium
  • CEO and CAO insider stock sales in June-July 2026 coincide with contract renewal uncertainty. Severity: low
  • No structural barrier prevents PBMs or Teladoc from in-sourcing coaching and dropping Omada. Severity: high
Rivals, as read in July 2026
RivalDirectionEvidence
Virta Healthlosing toPHTI's 2024 study found Virta's ketosis outcomes more clinically meaningful than Omada's
Lark HealthcontestingAI-only coaching model undercuts Omada's human-coach cost premium, as of 2026
Teladoc Health (Livongo)contestingDormant since $6.6B 2022 writedown but not structurally barred from re-entering, as of 2026
Hinge HealthcontestingCompetes directly in Omada's Joint and Muscle Health (MSK) product line
Questions people ask
Is Omada Health profitable?
Omada Health reported positive net income in Q4 2025 and positive adjusted EBITDA for full-year 2025, on revenue of $260.21 million (up 53% year-over-year), per its March 5, 2026 earnings release. Profitability is recent, not sustained across multiple years.
Who are Omada Health's biggest competitors?
Omada's closest rivals are Livongo (owned by Teladoc Health), Virta Health, Vida Health, Lark Health, and DarioHealth, with Hinge Health competing in its MSK line. A 2024 Peterson Health Technology Institute study found Virta's outcomes more clinically meaningful than Omada's.
Could AI replace Omada Health's coaches?
Omada has already automated parts of nutrition coaching with its own AI tools, OmadaSpark (May 2025) and Meal Map (October 2025). Rival Lark Health runs an AI-only coaching model positioned as cheaper, but Omada's PBM contracts and clinical data give it lock-in AI alone can't replicate yet.
Who owns Omada Health?
Omada Health went public on Nasdaq (ticker OMDA) on June 6, 2025, at $19 per share, raising $150 million. As of July 2026, insiders including CEO Sean Duffy held roughly 6.4% of shares outstanding; the rest trades publicly.
Does Omada Health actually work clinically?
Omada disputes an independent 2024 Peterson Health Technology Institute finding that its behavior-modification programs produced only marginal, not clinically meaningful, A1c reductions versus Virta Health's approach. Omada has since published its 30th peer-reviewed manuscript as of November 2025.
Is Teladoc a threat to Omada Health?
Teladoc already tried chronic-care coaching via its $18.5 billion 2020 Livongo acquisition, later written down by $6.6 billion in 2022, and remains dormant in this space as of mid-2026. Omada is not structurally protected if Teladoc re-enters aggressively.
Timeline
  • 2026-07-18BTIG Research upgraded OMDA to Strong-Buy; CEO and CAO also sold shares
  • 2026-07-15Announced first Investor Day for September 10, 2026 in New York
  • 2026-05-07Q1 2026 earnings: revenue $78.05M (+42% YoY), guidance raised to $322-330M
  • 2026-05-07Joined Eli Lilly Employer Connect as independent GLP-1 program administrator
  • 2026-03-05FY2025 results: revenue $260.21M (+53% YoY), positive Q4 net income, launched Omada for Cholesterol
  • 2025-11-06Announced GLP-1 prescribing offering, published 30th peer-reviewed manuscript
  • 2025-10-01Launched Meal Map, AI-powered nutrient-quality tool
  • 2025-06-06IPO on Nasdaq at $19/share, raised $150 million, valuation ~$1.1 billion
  • 2025-05-01Launched Nutritional Intelligence and OmadaSpark AI chat agent
  • 2024-04-01Peterson Health Technology Institute study found marginal outcomes vs Virta
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources